Reply Letter to PII
Reply letter to Piccoleto II : seeking an appropriate primary endpoint for DCB clinical trials
Piccoleto II: my interview during JIM 2020 on the 1 year outcome of the Piccoleto II study
1. What was the PICCOLETO II study design and what did it aim to assess?
2. What are the key outcomes and how do they compare to studies such as BASKET-SMALL II?
3. Were there limitations with PICCOLETO II?
4. In your opinion, how should PICCOLETO II influence practice?
5. What questions remain unanswered that require further research?